文献速递间质性肺疾病

法国儿童间质性肺病流行病学:RespiRare队列研究

Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort.
PubMed 文献 · Thorax · 2024-08-19

该研究基于法国RespiRare网络纳入2000至2022年790例儿童间质性肺病(chILD)患者,估算2022年患病率为44/百万儿童(95%CI 40.76-47.46),发病率为4.4/百万儿童(95%CI 3.44-5.56)。诊断中位年龄3个月,5年生存率在<2岁组为57.3%、2-18岁组为86%。

要点

  • chILD在法国的患病率和发病率高于既往描述。
  • 诊断中位年龄为3个月,16.9%为家族性形式。
  • 5年生存率<2岁组57.3%,2-18岁组86%。

核心结论

  • 该大型系统流行病学研究证实chILD的发病率和患病率高于既往描述。
  • 仍需优化病例收集并统一诊断和管理实践以开展国际研究。

研究设计与样本

  • 在RespiRare网络内开展多中心回顾性观察研究,纳入2000至2022年chILD患者。
  • 2022年2月至2023年进行前瞻性评估chILD发病率。
  • 共42个中心报告790例chILD患者。

主要发现

  • 2022年法国估计患病率为44/百万儿童(95%CI 40.76-47.46),计算发病率为4.4/百万儿童(95%CI 3.44-5.56)。
  • 诊断中位年龄为3个月,16.9%为家族性形式。
  • 肺活检和基因分析分别 performed 于23.4%和76.9%的患者。
  • <2岁组最常见病因是表面活性物质代谢障碍(16.3%)和婴儿神经内分泌细胞增生(11.8%)。
  • 2-18岁组常见病因为弥漫性肺泡出血(12.2%)、结缔组织病(11.4%)、过敏性肺炎(8.8%)和结节病(8.8%)。

关键数值与推荐

  • 管理主要包括氧疗(52%)、皮质类固醇冲击(56%)、口服皮质类固醇(44%)、阿奇霉素(27.2%)、肠内营养(26.9%)、免疫抑制剂(20.3%)和羟氯喹(15.9%)。
  • 诊断前<2岁患者5年生存率为57.3%,2-18岁患者为86%。

临床怎么用

  • 临床中应认识到chILD的患病率和发病率可能高于既往估计。
  • 对<2岁患儿需考虑表面活性物质代谢障碍和婴儿神经内分泌细胞增生等病因。
  • 对2-18岁患儿需考虑弥漫性肺泡出血、结缔组织病、过敏性肺炎和结节病等病因。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Interstitial lung disease in children (chILD) are rare and mostly severe lung diseases. Very few epidemiological data are available in limited series of patients. The aim of this study was to assess the prevalence and incidence of chILD in France. METHODS: We performed within the RespiRare network a multicentre retrospective observational study in patients with chILD from 2000 to 2022 and a prospective evaluation of chILD's incidence between February 2022 and 2023. RESULTS: chILD was reported in 790 patients in 42 centres. The estimated 2022 prevalence in France was 44 /million children (95% CI 40.76 to 47.46) and the computed incidence was 4.4 /million children (95% CI 3.44 to 5.56). The median age at diagnosis was 3 months with 16.9% of familial forms. Lung biopsy and genetic analyses were performed in 23.4% and 76.9%, respectively. The most frequent chILD aetiologies in the <2 years group were surfactant metabolism disorders (16.3%) and neuroendocrine cell hyperplasia of infancy (11.8%), and in the 2-18 years group diffuse alveolar haemorrhage (12.2%), connective tissue diseases (11.4%), hypersensitivity pneumonitis (8.8%) and sarcoidosis (8.8%). The management included mainly oxygen therapy (52%), corticosteroid pulses (56%), oral corticosteroids (44%), azithromycin (27.2%), enteral nutrition (26.9%), immunosuppressants (20.3%) and hydroxychloroquine (15.9%). The 5-year survival rate was 57.3% for the patients diagnosed before 2 years and 86% between 2 and 18 years. CONCLUSION: This large and systematic epidemiological study confirms a higher incidence and prevalence of chILD than previously described. In order to develop international studies, efforts are still needed to optimise the case collection and to harmonise diagnostic and management practices.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Fletcher C, Hadchouel A, Thumerelle C, et al. Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort. Thorax. 2024. PMID: 38964860. doi:10.1136/thorax-2023-221325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。